167 results about "Addiction" patented technology

The invention can provide compounds, analogs of blebbistatin, effective and selective inhibitors of nonmuscle myosin II relative to cardiac myosin II. Compounds can be used in the method of treating a disease, disorder, or medical condition in a patient, comprising modulating myosin II ATPase, such as treatment of substance abuse relapse disorder, or of renal disease, cancer and metastasis, benign prostate hyperplasia, hemostasis or thrombosis, nerve injury including retinal damage, lung fibrosis, liver fibrosis, arthrofibrosis, wound healing, spinal cord injury, periodontitis, glaucoma and immune-related diseases including multiple sclerosis; or wherein the disease, disorder, or medical condition comprises addiction including abuse of or addiction to anything classified as a Substance-Related or Addictive Disorder in the Diagnostic and Statistical Manual of Mental Disorders (DSM), such as, but not limited to, cocaine, opioids, amphetamines, ethanol, cannabis / marijuana, nicotine, and activities including gambling.Compounds are of general formulawith substituents as defined herein.

Provided is a polypeptide which contains a polypeptide having at least 80%, 85%, 90%, 95%, or 99% identity to amino acid sequence MTYRPGYNPFG (SEQ ID NO: 41) or amino acid sequence AKGYYRPYGVPV (SEQ ID NO: 22), or a polypeptide having one or more amino acid substitutions, deletions and / or additions relative to the amino acid sequence as shown in SEQ ID NO: 41 or 22. The provided polypeptide can interfere with the binding of a Brag2 synaptic protein to the C terminus of an AMPA receptor, thereby inhibiting NMDA-mediated excessive endocytosis of an AMPA receptor and neuronal apoptosis, and playing a role in protecting neuronal cell activity. Therefore, the polypeptide has application prospects and potential development values as a drug for treating nervous system diseases such as strokes, depression, Alzheimer's disease and drug addiction.

The invention discloses an addiction-related epitope intelligent prediction and antibody optimization design method, and belongs to the field of medicine.The design method specifically comprises the following steps that firstly, multi-source heterogeneous biological information data are integrated, and the potential space structure, dynamic stability and regulation and control characteristics of an epitope are extracted; iI, identifying a low-immunogenicity region in the addiction target, and generating a high-adaptability candidate epitope according to the identified low-immunogenicity region; iII, optimizing antibody design according to the high-adaptability candidate epitopes, and dynamically adjusting the antibody design according to real-time molecular dynamics simulation feedback; according to the method, double optimization of antibody affinity and safety can be realized, the design efficiency and accuracy are improved, the problems of blind screening and low-efficiency verification in a traditional method are avoided, and the recognition redundancy of the antibody is improved, so that the effective period of a drug is prolonged, and the off-target risk is reduced.

Disclosed in the present invention are a drug for treating or preventing methamphetamine addiction, and the use. Also disclosed is a new use of an ERK inhibitor. In the present invention, the use of an ERK inhibitor in drug addiction is studied. The inhibitory effect of GDC-0994 in the treatment of methamphetamine addiction is studied by means of methamphetamine addiction models (including a place preference model and a self-administration experiment model), and it is found that the administration of the ERK inhibitor GDC-0994 can significantly reduce the seeking and ingesting of methamphetamine in animals, that is, the ERK inhibitor GDC-0994 can antagonize methamphetamine addiction, this indicates that the inhibition of ERK by GDC-0994 can effectively treat methamphetamine addiction.

Alkoxy-substituted N-benzyl-2-phenylacetamide compounds and derivatives are G-protein coupled receptor (GPR) 88 modulators for use in the treatment of a disease mediated by GPR88. Indications include Tourette's Syndrome, Huntington's Disease (HD), Addiction, Parkinson's Disease (PD), Schizophrenia, and Attention Deficit Hyperactivity Disorder (ADHD), choreiform movements, speech delay, learning disabilities, depression, hyperkinetic movement disorders characterised by chorea and / or dystonia, psychosis, cognitive deficits in schizophrenia, affective disorders, bipolar disorder, Alzheimer's disease and basal ganglia disorders.

This invention relates to the field of pharmaceutical technology, and discovers that the natural products boldinine and norboldinine can be used as NTSR1 (Neurotensin receptor-1, NTSR1) receptor antagonists and their applications. The compounds are boldinine and norboldinine ((+)-Laurolitsine), which have NTSR1 receptor antagonistic activity and are NTSR1 receptor antagonists that can prevent and treat alcohol poisoning, addiction, schizophrenia, autism spectrum disorder, and mood disorders. Accordingly, this invention can provide novel NTSR1 receptor antagonist prospective compounds with clear targets for the above-mentioned related diseases.

The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of e.g. depression, Alzheimer's disease, schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder. Exemplary compounds are e.g. 3-((1H-pyrazol-4-yl)methyl)-6′-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives and related compounds. The present description discloses the synthesis and characterisation of exemplary compounds, pharmacological data thereof, as well as exemplary tablet formulations comprising the compounds of the invention (e.g. page 83 to page 110; examples 1 to 33; reference example 1; test examples 1 and 2; tables 1 to 4).

Technologies are provided for predicting an individual's likelihood of addiction or relapse to pharmaceuticals that include controlled or addictive substances. The prediction can be used to generate an alert that, in some aspects, prevents care provider actions in an electronic health record system that are related to the addictive pharmaceutical until the prediction is acknowledged. Further, the data used as input in the predictive modeling can be disassociated from the prediction after the prediction is generated.

The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt and / or solvate thereof. The invention also relates to the use of the compounds of formula (I) as a medicament, in particular for the prevention or treatment of obsessive-compulsive disorder and related behaviors, including addiction, obsessive-compulsive disorder and dietary disorder, and neurodegenerative diseases, such as Parkinson's disease or Alzheimer's disease.

The present application relates to cost-effective, practical and scalable synthetic routes for the syntheses for psilocybin (Formula I) and its major metabolite psilocybin (Formula II) and their pharmaceutically acceptable salts. These compounds are useful for the treatment or prevention of mental health disorders, such as major depressive disorder, anxiety and addiction disorders, among others CNS disorders.

Disclosed herein are aldehyde dehydrogenase (ALDH-2) inhibitor compounds, such as a compounds of Formula (I) or Formula (II), pharmaceutical compositions comprising these inhibitor compounds, and uses of these compounds and compositions, such as in the methods for safely treating chemical dependency on a substance or condition of addiction, such as alcohol, nicotine, cocaine, opiates, amphetamines, and compulsive eating disorder, and / or anxiety disorder, each individually or concurrent.

Methods of treating tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, ADHD or addiction with (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid or a pharmaceutically acceptable salt thereof are provided. Methods of treating tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, ADHD or addiction with (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid are provided. Also provided are therapeutic compositions that may be used to improve one or more symptoms of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, ADHD or addiction.

The present invention relates to a compound, of the formula:Wherein variables are as defined in the specification and pharmaceutical composition comprising thereof, more specifically compound of the present invention is thiophenyl and pyrrolyl azepine compound; The compound is serotonin receptor (5-HT2c) ligand, useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT2c) is desired (e.g. addiction, anxiety, depression, obesity, and others).

The invention provides a juvenile network addiction early warning and reminding method and system based on physiological parameters, and belongs to the field of network addiction early warning, and the method comprises the steps: obtaining a facial image, a facial video stream and audio data of a user, and extracting the physiological feature data of the user from the facial image, the facial video stream and the audio data; sending the physiological feature data of the user to a background server; the background server is used for calculating physiological parameters based on the physiological feature data of the user, determining psychological parameters based on the questionnaire text data, the network application use data and the physiological parameters of the user, and calculating an addiction risk score based on the physiological parameters and the psychological parameters; in response to the received addiction risk score of the background server, if the addiction risk score is not less than a preset addiction risk threshold, determining a target early warning level based on the addiction risk score; and generating early warning information based on the target early warning level. According to the application, the addiction state of the juveniles can be accurately monitored and early warned.

A compound having a structure of formula (I), (II), (III), (IV), (V), (VI), or a pharmaceutically acceptable salt, a tautomer, or a solvate thereof for use in treating opioid addiction, withdrawal and / or dependence and / or loss of opioid induced analgesia and / or occurrence of opioid induced hyperalgesia in a subject in need thereof.

The present invention provides a composition for use as anti-addiction in mitragynine addiction symptoms, characterized in that the composition comprises FPL 64176 as an active ingredient by reducing levels of calretinin and dopamine in a subject's brain.

The invention belongs to the field of network addiction detection, and provides a network space addiction behavior index system construction method and device, equipment and a medium, and the method comprises the steps: obtaining an index and an addiction level of a network space addiction behavior, and determining a visual angle; performing two-point anchor point selection processing on the visual angle to obtain an anchor point set; according to the anchor point set, a similarity graph, a diversity graph and a consistency graph of the anchor points are constructed, and the similarity graph, the diversity graph and the consistency graph are used for representing the incidence relation of the view angles; performing fusion calculation on the diversity graph and the consistency graph of the anchor points to obtain a weighted similarity matrix; carrying out eigendecomposition on the weighted similarity matrix to obtain low-dimensional embedded representation, and carrying out supervised training on the low-dimensional embedded representation through a loss function to obtain a network space addiction behavior index system; and network addiction detection is carried out through the network space addiction behavior index system. According to the invention, the accuracy of user network addiction level identification is improved.

The invention discloses an addiction prevention method suitable for juveniles, which solves the problem that the juveniles are easy to addict when using a mobile intelligent terminal to a certain extent by changing the mode of a graphic decoding module, or a graphic display module, or an audio decoding module or an audio display module of a hardware part of the mobile intelligent terminal.

This invention provides a class of multi-target heteropeptides based on N-4-piperidinyl-N-phenylpropionamide analogs and neuropeptide FF. These heteropeptides use the small-molecule N-4-piperidinyl-N-phenylpropionamide and the polypeptide-structured neuropeptide FF as chemical templates. A series of peptide-small-molecule hybrid peptides are obtained by chemically coupling the pharmacophores of the N-4-piperidinyl-N-phenylpropionamide analog and the neuropeptide FF. In vivo pharmacological activity identification in animals shows that these heteropeptides possess analgesic activity without opioid-like side effects such as addiction and respiratory depression. Furthermore, compounds 1-4 and compounds 7-9 do not exhibit analgesic tolerance and can be used for long-term analgesic treatment of chronic pain. Therefore, these heteropeptides based on N-4-piperidinyl-N-phenylpropionamide analogs and neuropeptide FF can be used to prepare analgesic drugs.

A method of modulating a brain activity of a mammal is achieved by subjecting the mammal to transcranial magnetic stimulation (TMS) with a TMS apparatus at random variable pulse intervals for a time sufficient to modulate said brain activity. The method can also be used by administering electric stimulation to the brain. Improvement in a physiological condition or a clinical condition is achieved. Conditions to be treated include but are not limited to PTSD, autism spectrum disorder addiction (SUD) and Alzheimer's disease.

1. Name of the Design Product: Mobile Device Shell (Anti-Addiction). 2. Use of the Design Product: It is used as the shell of a mobile electronic device and can control the on / off switch of the device screen lock. 3. Design Key Points of the Design Product: Lies in the shape. 4. Picture or Photograph that Best Illustrates the Design Key Points: Perspective View 1.

Cannabinoid analogs may exhibit anti-inflammatory properties such as by inhibition of cannabinoid type 2 (CB2) receptors. Pharmaceutical compositions comprising the cannabinoid analogs may be used to treat various diseases and conditions in mammals, including pain, anxiety, a sleep disorder, addiction, epilepsy, depression, post-traumatic stress disorder or Alzheimer's disease. In some examples, the pharmaceutical compositions may be administered for treating a cognitive disorder or for improving cognition.

Methods of treatment and treatment systems for performing radiomodulatory stereotactic radiosurgery to treat brain disorders in which target neural tissues associated with the brain disorder are sensitized to radiation by administration of a molecular substance and / or non-targeted critical structures are protected from radiation by a molecular substance, in order to treat disorders of brain circuitry. Specific embodiments disclose means for treating pain, obesity and drug addiction.

The invention discloses an intelligent ring early warning system for multi-dimensional hand action monitoring, and relates to the technical field of intelligent rings, and the system comprises a data acquisition module, a gesture extraction module, a behavior judgment module, an early warning module and a personalized module. According to the invention, scene-based and personalized judgment is adopted, and addiction critical points in different situations are accurately adapted, the behavior judgment module calculates behavior diversity indexes based on the distribution of three types of hand operation units and dynamically judges the addiction risk in combination with scene information and a personalized attention baseline, and the personalized module dynamically judges the addiction risk through clustering analysis of historical behaviors of a user. Different use scenes are divided, and the exclusive judgment base line of each scene is continuously updated, so that the system not only can adapt to risk identification of easily addicted scenes, but also can dynamically adjust the judgment standard along with user behavior habit changes, it is ensured that critical points about to be addicted can be accurately perceived in various scenes, misjudgment or missed judgment caused by general standards is avoided, and the user experience is improved. And the early warning accuracy is improved.

Provided herein are compounds of Formula (I) or pharmaceutically acceptable salts thereof. Further disclosed are nanoparticles comprising one of the compounds and methods of using the same to treat drug addiction, drug dependence, drug excess, opioid use disorder, pain, chronic pain, fibromyalgia, arthritis, or obesity. (I)

The application belongs to the technical field of medicines, and relates to an N-H aporphine nitrogen-containing heterocyclic derivative, a preparation method and application thereof.The N-H aporphine nitrogen-containing heterocyclic derivative comprises a compound shown in a general formula M, isomers thereof and pharmaceutically acceptable salts or hydrates thereof.The application introduces a nitrogen-containing heterocyclic ring into an aporphine derivative, and the disclosed N-H aporphine nitrogen-containing heterocyclic derivative can be applied in the preparation of medicines for preventing and / or treating obesity, urinary incontinence, depression, anxiety, obsessive-compulsive disorder, epilepsy, schizophrenia, pain, diabetes and drug addiction.

The application of the modulator for activating Hcar2 in the preparation of a drug for cocaine addiction withdrawal belongs to the technical field of biological medicine. The technical problem to be solved is to provide a new cocaine addiction withdrawal treatment target and a modulator for activating the target. The technical solution is that the application first discovers Hcar2 as a target and the application of the modulator for activating Hcar2 in the preparation of a drug for treating cocaine addiction withdrawal, solves the clinical dilemma of the lack of specific treatment drugs for cocaine addiction withdrawal, regulates NAc microglial cell homeostasis through the Hcar2 modulator, is different from traditional neuronal signal pathway targets, the Hcar2 modulator regulation of the application belongs to the neuroimmunomodulation mechanism, and can be verified through a cocaine rat self-administration model, thereby improving the clinical conversion value of the research results.

A method for verifying transactions in a metaverse environment is disclosed. The method comprises: detecting a first user involved in an activity using user biometrics, wherein the first user is in focused attention state or addiction state; identifying a second user interacting with the first user during a transaction; identifying an intention of the second user interacting with the first user; determining a presence of an abnormality in a physiological state of the first user; and recommending to the first user to focus on the transaction.

Methods and systems for improving medical conditions by delivering a focused ultrasound signal to target sites of the brain. The focused ultrasound signal can have a mechanical index of between about 1.0 to about 8.0 and / or an acoustic pressure of between about 1.0 MPa to about 3.0 MPa. The medical condition can comprise addiction (including binge eating), anxiety disorders and anxiety associated disorders, tinnitus, neurodegenerative disorders, neuropsychiatric disorders, cognitive disorders, neurodevelopmental disorders, post-traumatic stress disorder, stroke recovery, and combinations thereof.

The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of e.g. depression, Alzheimer's disease schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder. Exemplary compounds are e.g. 1-((1H-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2H-imidazol-2-one derivatives and related compounds. The present description discloses the synthesis and characterisation of exemplary compounds, pharmacological data thereof, as well as exemplary tablet formulations comprising the compounds of the invention (e.g. page 100 to page 143; examples 1 to 167; test examples 1 and 2; tables 1 to 4).